The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Current and future treatment options for cholangiocarcinoma
John Bridgewater, BA, MBBS, MRCP, PhD, University College London Hospitals NHS Foundation Trust, London, UK, gives his thoughts on the current treatment of advanced cholangiocarcinoma in the UK, and discusses a new treatment option – pemigatinib – which is now available in the UK. Patients with advanced cholangiocarcinoma have historically been able to only access limited treatment options including surgery and chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Disclosures
Prof. Bridgewater reports advisory capacity to Incyte.
